AVITA Medical, Inc. (RCEL) Misses Q4 EPS by 10c, provides guidance

AVITA Medical, Inc. (NASDAQ: RCEL) reported Q4 EPS of ($0.44), $0.10 worse than the analyst estimate of ($0.34). Revenue for the quarter came in at $18.4 million versus the consensus estimate of $23.2 million.

GUIDANCE:

AVITA Medical, Inc. sees FY2025 revenue of $100-106 million, versus the consensus of $89.7 million. Expect to generate free cash flow in the second half of 2025 and reach GAAP profitability during Q4 2025

For earnings history and earnings-related data on AVITA Medical, Inc. (RCEL) click here.

You May Also Be Interested In

• Trump Bought At Least $100,001 In Palantir Shares, Disclosure Shows - Bloomberg
• Trump's annual disclosures show $236 million in crypto proceeds, gifts worth $370,000
• Mitsubishi Electric wins JAXA subsidy for digital satellite payload